The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
allogeneic stem cell transplantation
chronic myeloid leukemia
tyrosine kinase inhibitor
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
08
02
2022
received:
22
11
2021
accepted:
31
03
2022
pubmed:
9
4
2022
medline:
10
8
2022
entrez:
8
4
2022
Statut:
ppublish
Résumé
The introduction of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) treatment has dramatically improved the prognosis of CML patients and reduced the number of patients receiving allogeneic stem cell transplantation (allo-SCT). However, the impact of the newest-generation TKIs on the overall survival (OS) after allo-SCT has not been well described. To investigate the beneficial effects of TKIs on the prognosis after allo-SCT, we conducted a retrospective observational study using the Transplant Registry Unified Management Program database in Japan. We analyzed 1188 patients (male/female: 738/450; median age: 44 years; range: 16-75) who underwent their first allo-SCT between January 2001 and December 2018. We divided the patients into two groups according to the TKI treatment used before allo-SCT: group 1 was treated with the first generation TKI imatinib; group 2 was treated with the second generation TKIs nilotinib, dasatinib, or bosutinib and/or the third generation TKI ponatinib. We compared the post allo-SCT OS between the two groups. The 3-year OS rates (95%CI) of groups 1 and 2 were 59.3% (54.8%-63.5%) and 65.8% (61.6%-69.6%), respectively (p = 0.017). Multivariate analysis confirmed that group 2 had superior OS after allo-SCT compared to group 1 (p = 0.002). Other factors associated with superior prognosis were age ≤65, performance status (PS) 0/1, a 6/6 HLA-matched donor and chronic-phase (CP) disease status at allo-SCT. A subgroup analysis showed poor prognoses for patients who could not obtain a molecular response before allo-SCT and patients with positive T315I mutation in the BCR/ABL gene. In group 2, early allo-SCT was correlated with superior OS in patients with a blast-crisis disease status at allo-SCT (p = 0.001). The cumulative incidence of non-relapse mortality rate significantly decreased in group 2 (p = 0.0005). The post allo-SCT OS was improved both by pre- and post-management of allo-SCT and by the introduction of newer TKIs.
Substances chimiques
Protein Kinase Inhibitors
0
Dasatinib
RBZ1571X5H
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
442-456Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 18ek0510023h0002
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917-927. https://doi.org/10.1056/NEJMoa1609324
Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-2259. https://doi.org/10.1056/NEJMoa0912614
Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270. https://doi.org/10.1056/nejmoa1002315
Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486-3492. https://doi.org/10.1200/JCO.2011.38.7522
Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796. https://doi.org/10.1056/nejmoa1306494
Japanese Society of Hematology. Practical Guidelines for Hematological Malignancies 2nd ed. Japanese Society of 19 Hematology, ed.Kanehara Shuppan; 2020.
Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood. 2015;125(21):3230-3235. https://doi.org/10.1182/blood-2014-10-567784
Lübking A, Dreimane A, Sandin F, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transpl. 2019;54(11):1764-1774. https://doi.org/10.1038/s41409-019-0513-5
Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94(2):141-147. https://doi.org/10.1007/s00277-015-2322-2
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein HTJ, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2. 4th ed.; 2017.
Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. 2013;122:872-884.
Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15(12):1628-1633. https://doi.org/10.1016/J.BBMT.2009.07.004
El-Jawahri A, Le Blanc T, Van Dusen H, et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA J Am Med Assoc. 2016;316(20):2094. https://doi.org/10.1001/jama.2016.16786
Mackinnon S, Goldman JM. Bone marrow transplantation for patients with chronic myeloid leukaemia. Br J Hosp Med. 1988;39(3):226-230. https://doi.org/10.1056/nejm198601233140403
Drobyski WR, Pelz C, Kabler-Babbitt C, Hessner M, Baxter-Lows LA, Keever-Taylor CA. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia. Biol Blood Marrow Transpl. 1998;4(1):3-12. https://doi.org/10.1053/BBMT.1998.V4.PM9701386
Ohanian M, Kantarjian HM, Quintas-Cardama A, et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid Leukemia in accelerated phase. Clin Lymphoma Myeloma Leukemia. 2014;14(2):155-162. https://doi.org/10.1016/j.clml.2013.08.008
Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011;118(20):5697-5700. https://doi.org/10.1182/BLOOD-2011-07-367326
Xu LP, Xu ZL, Zhang XH, et al. Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia. Biol Blood Marrow Transpl. 2016;22(6):1080-1086. https://doi.org/10.1016/J.BBMT.2016.03.012